Presentation is loading. Please wait.

Presentation is loading. Please wait.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.

Published byWinfred Hardy Modified over 8 years ago

Similar presentations

Presentation on theme: "Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D."— Presentation transcript:

1 Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.

2 Stage Distribution Total Number of Patients = 74 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun9/46 (19.6%) 22/46 (47.8%) 9/46 (19.6%) 4/46 (8.7%) 1/46 (2.17%) 1/46 (2.17%) 46/46 (100%) Jul - Dec6/28 (21.4%) 10/28 (36%) 9/28 (32.1%) 0/28 (0%) 0/28 (0%) 3/28 (10.7%) 28/28 (100%) Jan-Dec15/74 (20.2%) 32/74 (43.2%) 18/74 (24.32%) 4/74 (5.40%) 1/74 (1.35%) 4/74 (5.4%) 74/74 (100%) Compiled by Uzma Nazim, M.D.

3 Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Preoperative Core 9/9 (100%) 22/22 (100%) 9/9 (100%) 3/4 (75%) 1/1 (100%) 1/1 (100%) 45/46 (97.82%) Jul – Dec Preoperative Core 4/6 (66.6%) 9/10 (90%) 9/9 (100%) 0/0 (0%) 0/0 (0%) 2/3 (66.6%) 24/28 (85.71%) Jan-Dec Preoperative Core 13/15 (86.6%) 31/32 (96.8%) 18/18 (100%) 3/4 (75%) 1/1 (100%) 3/4 (75%) 69/74 (93.24%) Mode of Diagnosis Total Number of Patients = 74 93.24% of patients had diagnosis established on preoperative core needle biopsy Exceptions Pt. with ADH on core biopsy 1/5 Pts. with implants2/5 Pt. with recurrence after 2009 palliative excision done1/5 Pt. unable to lie prone for stereotactic bx.1/5 Compiled by Uzma Nazim, M.D.

4 Tumor Board Discussion Total Number of Patients =74 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Discussed 8/9 (88.8%) 20/22 (90.9%) 9/9 (100%) 3/4 (75%) 1/1 (100%) 1/1 (100%) 42/46 (91.3%) Jul – Dec Discussed 4/6 (66.6%) 6/9 (66.6%) 7/9 (77.7%) 0 (0%) 1/1 (100%) 3/3 (100%) 21/28 (75%) Jan-Dec Discussed 12/15 (80%) 26/31 (83.8%) 16/18 (89%) 3/4 (75%) 2/2 (100%) 4/4 (100%) 63/74 (85.1%) 85.1% of patients were discussed in the multidisciplinary tumor conference Compiled by Uzma Nazim, M.D.

5 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun MDC seen 8/9 (88.8%) 19/22 (86.3%) 7/9 (77.7%) 4/4 (100%) 1/1 (100%) 0/1 (0%) 39/46 (84.78%) Jul – Dec MDC seen 5/6 (83.3%) 8/10 (80%) 6/9 (66.6%) 0 (0%) 0 (0%) 3/3 (100%) 22/28 (79%) Jan-Dec MDC seen 13/15 (87%) 27/32 (84%) 13/18 (72.22%) 4/4 (100%) 1/1 (100%) 3/4 (75%) 61/74 (82.4%) Multidisciplinary Assessment (Surgical, Medical and Radiation Oncologist) Total Number of Patients = 74 Exceptions: 13/74 (17.56%) Older than 70 yrs. declined radiation appointment in favor of mastectomy 7/13(53.84%) Under 70 yrs. declined radiation appointment in favor of mastectomy 5/13(38.46%) Patient transferred 1/13(7.6%) Compiled by Uzma Nazim, M.D.

6 Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Assigned 9/9 (100%) 21/22 (95.4%) 9/9 (100%) 3/4 (75%) 1/1 (100%) 1/1 (100%) 44/46 (95.65%) Jul – Dec Assigned 6/6 (100%) 9/10 (90%) 9/9 (100%) 0 (0%) 0 (0%) 3/3 (100%) 27/28 (96.4%) Jan-Dec Assigned 15/15 (100%) 30/32 (93.7%) 18/18 (100%) 3/4 (75%) 1/1 (100%) 4/4 (100%) 71/74 (95.9%) Nurse Navigation Total Number of Patients = 74 Exceptions 3/74(4.05%) * HCC pts. did not have full navigation by the nurse through treatment ----HCC notified. Compiled by Uzma Nazim, M.D.

7 Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 9/9 (100%) 22/22 (100%) 8/9 (88.8%) 4/4 (100%) 0/1 (0%) 0/1 (0%) 43/46 (93.4%) Jul – Dec Yes 6/6 (100%) 10/10 (100%) 9/9 (100%) 0 (0%) 0 (0%) 0/3 (0%) 25/28 (89.3%) Jan-Dec Yes 15//15 (100%) 32/32 (100%) 17/18 (94.4%) 4/4 (100%) 0/1 (0%) 0/4 (0%) 68/74 (92%) CAP Compliance Total Number of Patients = 74 Compiled by Uzma Nazim, M.D. Exceptions 6/74 (8.1%) Final surgery not done 5/6 (83.3%) Patient transferred 1/6 (16.66%)

8 Axillary Staging Total Number of Patients = 74 Total Number of Patients with Invasive Cancer = 59 Number node positive patients on needle biopsy5/59 (8.47%) Number of pts. with Stage IV disease 1/59(1.69%) Number of patients eligible for SLNB 53/59(89.8%) – Number of patients with SLNB46/53 (86.79%) Exceptions7/53(13.2%) Determined low risk (unlikely to change treatment plan)6/7(85.7%) Patient transferred 1/7(14.28%) Compiled by Uzma Nazim, M.D.

9 Axillary Dissection Total Number of Patients = 74 Total Number of Patients with Invasive Cancer = 59 Number of patients with stage IV 1/59 (1.69%) Number of patients with node positive disease 20/59(33.8%) Number of patients eligible for ALND 20 Number of patients with ALND 13/20 (65%) Exceptions7/20 (35%) Low risk for non-SLN mets. on MSKCC nomogram6/7 (85.7%) Final surgery not done yet 1/7 (14.28%) Compiled by Uzma Nazim, M.D.

10 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 6/9 (66.66%) 18/22 (81.8%) 5/9 (56%) 2/4 (50%) 0/1 (0%) 0/1 (0%) 31/46 (67.39%) Jul – Dec Yes 4/6 (66.6%) 8/10 (80%) 5/9 (56%) 0 (0%) 0 (0%) 0/3 (0%) 17/28 (60.71%) Jan-Dec Yes 10/15 (66.6%) 26/32 (81.25%) 10/18 (56%) 2/4 (50%) 0/1 (0%) 0/4 (0%) 48/74 (64.9%) Breast Conservation Total Number of Patients = 74 Number of early stage pts. (0, I and II) with breast conservation 48/65(74%) Mastectomies done 20/74(27%) Compiled by Uzma Nazim, M.D.

11 Post-lumpectomy Radiation Total Number of Patients =74 Number of patients with lumpectomy 48/74 (64.8%) Number of patients eligible for Radiation 48 – Number of patients radiated 44/48 (91.66%) Exceptions 4/48(8.3%) Co-morbidity and age >70 yrs. 1/4 (25%) Patient had mastectomy after initial lumpectomy 3/4 (75%) Number of patients radiated within 12 months 44/44(100%) Compiled by Uzma Nazim, M.D.

12 Post-Mastectomy Radiation Total Number of Patients = 74 Number of patients with mastectomy 20/74 (27%) Number eligible for radiation (>T3 or >N2)2/20(10%) Number of patients radiated2/2(100%) Number of patients radiated within 12 months2/2 (100%) Compiled by Uzma Nazim, M.D.

13 Systemic Chemotherapy - I Total Number of Patients = 74  ER negative patients with cancer13/74 (17.56%) Number eligible for chemotherapy(exclude DCIS)12/13 (92.3%) – Number treated with chemotherapy 9/12 (75%) Exceptions 3/12 (25%) Patient refused 1/3 (33.3%) Severe co-morbidities and age 2/3(66.6%)  Number with chemotherapy within 4 months9/9(100%) Exceptions0 (none) Compiled by Uzma Nazim, M.D.

14 Systemic Chemotherapy - II Total Number of Patients = 74  ER positive patients with cancer61/74 (82.43%) Number treated with chemotherapy23/61 (37.78%)  Number with chemotherapy within 4 months20/23 (87%) Exceptions3/23(13%) Pt. developed mirizzi’s syndrome1/3(33.3%) Pt. had wound infection1/3(33.3%) Chemo was within 4 months from cancer diagnosis original biopsy showed ADH1/3(33.3%) Compiled by Uzma Nazim, M.D.

15 Systemic Endocrine Therapy Total Number of Patients = 74  Number of ER positive patients 61/74 (82.43%) Number treated with endocrine therapy 52/61 (85.24%) Exceptions 9/61 (14.75%) Determined risk > benefit 5/9 (55.6%) Patients with co morbidities 3/9 (33.33%) Patient non compliant 1/9 (11.11%)  Number with endocrine therapy within 1 year 52/52 (100%) Compiled by Uzma Nazim, M.D.

16 Rehabilitation Total Number of Patients =74 Number enrolled in CPRP (PT/OT)36/74 (49%) Exceptions37/74 (50%) Services were available but structured program is pending definitive establishment, whereby every patient gets a baseline arm girth and shoulder range of motion documented; prospective data is maintained with a pre-designed schedule. Pts. enrolled in CPRP in 2011 24/107 (22.43%) Pts. enrolled in CPRP in 2012 36/74 (49%) Improvement over 2011 26.57% Compiled by Uzma Nazim, M.D.

17 Genetic Counseling Total Number of Patients = 74 Number of patients with family history or < 45 years49/74 (66.2%) Number received genetic counseling19/49(39%) – Number tested14/19(74%) Positive3/14(21.4%) Negative11/14(79%) – Number refused testing 5/19(26.3%) Exceptions 30/49(61.2%) Did not meet NCCN criteria 24/30(80%) No documentation in the chart6/30(20%) Compiled by Uzma Nazim, M.D.

18 Time Frame Trial / StudyEligible N (%) Participation N (%) Jan – Jun B-SMART33(100%) CCIP20(0%) SPOC1712(70.6%) MULTIPLE STUDIES2219(86.4%) Total 44/46(96%)34/44(77%) Jul - Dec B-SMART32(66.66%) CCIP55(100%) SPOC62(33.3%) MULTIPLE STUDIES1110(90.9%) Total 27/28(96.4%) 19/27(70.3%) TOTAL71/74(95.9%)53/71(75%) Trial Participation Total Number of Patients = 74 Patients participated in trials for 2012 53/71(75%)

Download ppt "Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D."

Similar presentations

Evidence for adjuvant radiation therapy benefiting breast cancer patients with 1 to 3 positive lymph nodes treated with a modified radical mastectomy and.

Evidence for adjuvant radiation therapy benefiting breast cancer patients with 1 to 3 positive lymph nodes treated with a modified radical mastectomy and.
Baptist Health System General Surgery Residency Program

Baptist Health System General Surgery Residency Program
Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.
Pimp Session: Breast By James Lee, MD.

Pimp Session: Breast By James Lee, MD.
Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.

†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.
Breast Cancer in Pregnancy

Breast Cancer in Pregnancy
Role of Nodal Irradiation in Breast Cancer

Role of Nodal Irradiation in Breast Cancer
An update for Illinois Nurses Elizabeth A. Peralta, MD The Breast Center at SIU Springfield, IL May 2011.

An update for Illinois Nurses Elizabeth A. Peralta, MD The Breast Center at SIU Springfield, IL May 2011.
The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.
Breast Reconstruction: Outcomes Analysis Michael J Bass, MD, JD www.drmichaeljbass.com Michael J Bass Plastic Surgery, PLLC.

Breast Reconstruction: Outcomes Analysis Michael J Bass, MD, JD Michael J Bass Plastic Surgery, PLLC.
Sentinel Lymph Node Dissection (SND)

Sentinel Lymph Node Dissection (SND)
What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)

What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
AJCC TNM Staging 7th Edition Breast Case #3

AJCC TNM Staging 7th Edition Breast Case #3
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.

By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Similar presentations

Ads by Google